Current issue
Archive
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
2/2016
vol. 97 abstract:
SHORT COMMUNICATIONS
The new RNAi-based therapy for brain tumors
Katarzyna Rolle
1
,
Jan Barciszewski
1
BioTechnologia vol. 97(2) C pp. 153-155 C 2016
Online publish date: 2016/07/20
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
The subject matter of this invention includes a sequence of double-stranded RNA: ATN-RNA, intervention using interference RNA intervention (iRNAi); the use of a sequence of double-stranded RNA: ATN-RNA, a method of treating (a) brain tumor and a method of inhibiting brain tumor cells which express tenascin, a kit for inhibiting cancer cell which expresses tenascin and a method for a kit preparation in a brain tumor therapy. Malignant gliomas preferentially express a number of surface markers that may be exploited as therapeutic targets, including tenascin-C, an extracellular matrix glycoprotein ubiquitously expressed by malignant gliomas, which probably contributes to the tumor cell adhesion, invasion, migration, and proliferation. For tenascin-C inhibition, the iRNAi approach has been applied.
|